Seilern Investment Management Ltd Has $96.89 Million Stake in Edwards Lifesciences Corporation $EW

Key Points

• Seilern Investment Management Ltd has decreased its position in Edwards Lifesciences Corporation by 9.5%, selling 130,584 shares, and now holds 1,238,875 shares valued at approximately $96.89 million.
• Insiders have also been selling shares; for example, VP Daniel J. Lippis sold 4,114 shares, reducing his ownership by 15.75%.
• Despite some sell-offs, several institutional investors have increased their stakes, with 79.46% of Edwards Lifesciences currently owned by institutional investors and hedge funds.

Seilern Investment Management Ltd lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,238,875 shares of the medical research company's stock after selling 130,584 shares during the quarter. Edwards Lifesciences makes up 6.4% of Seilern Investment Management Ltd's holdings, making the stock its 5th largest position. Seilern Investment Management Ltd owned about 0.21% of Edwards Lifesciences worth $96,892,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Quantbot Technologies LP bought a new stake in Edwards Lifesciences during the first quarter valued at about $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $27,000. SouthState Corp purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $27,000. Global X Japan Co. Ltd. raised its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC grew its position in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Robert W. Baird raised their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Finally, Morgan Stanley boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.17.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $0.43 on Friday, reaching $74.12. The company's stock had a trading volume of 2,103,842 shares, compared to its average volume of 4,457,345. The stock's 50 day simple moving average is $78.76 and its 200-day simple moving average is $75.49. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a market capitalization of $43.52 billion, a P/E ratio of 10.70, a PEG ratio of 3.63 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm earned $0.70 earnings per share. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.